Clinical Trials Logo

Clinical Trial Summary

Over the past 15 years, intravenous chemotherapy has become the most popular conservative (eye-saving) method for retinoblastoma treatment because it is often effective and usually safe. In recent years, there has been much interest in providing highly focused (focal) chemotherapy to a diseased organ including the liver, brain, and eye. With focused chemotherapy, the chemotherapy drugs are injected directly into the ophthalmic artery (the artery that supplies blood to the eye). A benefit of focal chemotherapy delivery is that it decreases the chance of toxicity to other organs such as bone marrow suppression (causing low blood counts) and the development of other cancers in the future.


Clinical Trial Description

The management of retinoblastoma includes systemic chemotherapy (carboplatin, etoposide, and vincristine), thermotherapy, cryotherapy (freezing treatment), laser photocoagulation, plaque radiotherapy, external beam radiotherapy, and enucleation. The treatment is tailored to each individual case. Over the past 15 years, intravenous chemotherapy has risen as the most popular conservative (eye-saving) method for retinoblastoma management because it is effective and safe. In recent years, there has been keen interest in providing chemotherapy more focally to a diseased organ including the liver, brain, and eye. The benefit of focal chemotherapy delivery is to avoid toxicity to other organs and this toxicity includes the risk of future cancers. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00857519
Study type Interventional
Source Wills Eye
Contact
Status Completed
Phase N/A
Start date January 2009
Completion date April 2014

See also
  Status Clinical Trial Phase
Recruiting NCT04564521 - Nitroglycerin for Intra-arterial Chemotherapy in Pediatric Retinoblastoma. N/A
Recruiting NCT02933333 - G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Phase 4
Withdrawn NCT01151748 - Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma Phase 2
Completed NCT01048892 - Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Phase 1
Active, not recruiting NCT00360750 - Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye N/A
Completed NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2
Enrolling by invitation NCT06227962 - Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors
Completed NCT01661400 - Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors Phase 1
Terminated NCT02617862 - PCI Imaging System in Pediatric Ophthalmology N/A
Recruiting NCT02329002 - SPT Screening in Irradiated Hereditary Retinoblastoma Survivors N/A
Terminated NCT01466855 - A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma Early Phase 1
Completed NCT01505569 - Auto Transplant for High Risk or Relapsed Solid or CNS Tumors N/A
Completed NCT00002515 - Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Phase 2
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Completed NCT06367569 - Evaluation of MRI of the Pineal Gland in Retinoblastoma
Completed NCT02193724 - Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma
Completed NCT01884194 - Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging N/A
Terminated NCT01393769 - Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage Phase 2
Completed NCT00006246 - Busulfan in Treating Children and Adolescents With Refractory CNS Cancer Phase 1
Terminated NCT00003926 - Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Phase 1